Biohaven Ltd. (NYSE: BHVN) has taken center stage in the biopharmaceutical sector after releasing positive results from its ...
(Reuters) - Biohaven has met the main goal in a study evaluating its drug in patients with an inherited disease that mainly ...
First clinical data of VO659 demonstrated 28% mean reduction in CSF mutant HTT at day 85 in HD patients in 40 mg dose cohort with an effect after the first dose No sustained ...